Analyst Consensus ?
ConsensusHold23 ratings
Bullish1356.5%
Neutral939.1%
Bearish14.4%
IDEXX Laboratories, Inc. · IDXX · FY2026 Q3 · Calendar Q4 2026
IDEXX raises 2026 outlook as diagnostics, placements and software support growth
IDEXX’s Q3 analysis points to continued growth support from companion-animal diagnostics, instrument placements, product expansion and software, while currency sensitivity, acquisition integration and veterinary visit trends remain key counterweights.
Reported Before market openNASDAQHealthcare
$43.42B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $3.73
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $1.19B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+19.5%
Event window
SPY move
+0.5%
Same window
Abnormal move
+18.9%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
IDXXSPY benchmark
Ask FN2 about IDXX FY2026 Q3
Transcript, numbers and history already loaded
What drove IDXX's +19.5% move after FY2026 Q3 earnings?What changed in IDXX's guidance and outlook in FY2026 Q3?Give me the bull and bear case for IDXX after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year 2026 revenue and EPS guidance after strong Q3 performance and an ezyVet contribution. Instrument placements reached 5.78 thousand, with nearly half outside the U.S.; the company also highlighted software integration following the ezyVet and Covet acquisitions.
Guidance delta
Raised the full-year 2026 revenue outlook to $4.741–$4.767 billion and EPS guidance to $14.96–$15.16 per share, according to the supplied Q3 analysis.
Key takeaways
- The supplied analysis describes 10% organic revenue growth in Q3 and raised full-year revenue and EPS guidance.
- InVue Dx placements reached 5.78 thousand, and nearly half were outside the U.S.
- Management cited CancerDx, Catalyst ProBNP and continued InVue Dx menu expansion as product drivers.
- ezyVet and Covet are being integrated with VetConnect PLUS and Vello; software and AI are described as growth opportunities.
Management priorities
- Expand InVue Dx adoption and add tests to its menu.
- Extend CancerDx with planned panel additions and develop the Multi-Q point-of-care launch.
- Integrate ezyVet and Covet with VetConnect PLUS and Vello while continuing international expansion.
Follow IDXX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$664.9Current
$247Low
$643.72Average
$830High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 2, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Neutral | Neutral | Maintain | Oct 27, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 16, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 11, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Stifel | Buy | Buy | Maintain | Mar 31, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 9, 2026 |
| BTIG | Buy | Buy | Maintain | Feb 3, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Nov 4, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Jul 17, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Apr 21, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 17, 2024 |
| Atlantic Equities | Neutral | Overweight | Downgrade | Aug 2, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 13, 2021 |
| Guggenheim | Neutral | Buy | Downgrade | Jul 12, 2021 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 22, 2019 |
| Canaccord Genuity | Buy | Buy | Maintain | May 2, 2019 |
| Bank of America | Buy | Buy | Maintain | Nov 2, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | Jan 16, 2018 |
| Aegis Capital | Sell | Sell | Maintain | Jun 1, 2017 |
| CL King | Neutral | Neutral | Maintain | Apr 1, 2016 |
| Raymond James | Market Perform | Outperform | Downgrade | Aug 28, 2015 |
| Feltl & Co. | Hold | Sell | Upgrade | Jul 23, 2015 |
| Bank oferica | Buy | Buy | Maintain | Apr 20, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $664.9. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $627 | $562.47 | -5.7% | Oct 27, 2026 |
| Goldman Sachs | Matt Dellatorre | $740 | $547.18 | +11.3% | Oct 16, 2026 |
| Barclays | Glen Santangelo | $710 | $595.76 | +6.8% | Aug 11, 2026 |
| UBS | Analyst unavailable | $620 | $559.86 | -6.8% | Jul 27, 2026 |
| UBS | Andrea Alfonso | $640 | $569.17 | -3.7% | Apr 28, 2026 |
| Piper Sandler | Analyst unavailable | $750 | $644.61 | +12.8% | Feb 9, 2026 |
| Barclays | Glen Santangelo | $800 | $642.94 | +20.3% | Feb 5, 2026 |
| UBS | Andrea Alfonso | $730 | $639.6 | +9.8% | Feb 3, 2026 |
| BTIG | Analyst unavailable | $800 | $639.6 | +20.3% | Feb 3, 2026 |
| Barclays | Glen Santangelo | $850 | $706.65 | +27.8% | Dec 8, 2025 |
| Morgan Stanley | Analyst unavailable | $805 | $721.04 | +21.1% | Nov 4, 2025 |
| UBS | Analyst unavailable | $750 | $722.94 | +12.8% | Nov 4, 2025 |
| BTIG | Analyst unavailable | $830 | $722.94 | +24.8% | Nov 4, 2025 |
| Jefferies | Keith Devas | $830 | $722.94 | +24.8% | Nov 4, 2025 |
| Leerink Partners | Analyst unavailable | $785 | $722.94 | +18.1% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $775 | $722.94 | +16.6% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $700 | $628.54 | +5.3% | Oct 31, 2025 |
| UBS | Andrea Alfonso | $720 | $638.89 | +8.3% | Oct 1, 2025 |
| Morgan Stanley | Analyst unavailable | $722 | $641.94 | +8.6% | Aug 5, 2025 |
| BTIG | Analyst unavailable | $785 | $641.94 | +18.1% | Aug 5, 2025 |
| Stifel Nicolaus | Analyst unavailable | $640 | $682.78 | -3.7% | Aug 4, 2025 |
| Stifel Nicolaus | Jonathan Block | $510 | $495.73 | -23.3% | Jun 24, 2024 |
| Barclays | Analyst unavailable | $590 | $507.68 | -11.3% | Feb 8, 2023 |
| J.P. Morgan | Analyst unavailable | $550 | $487.04 | -17.3% | Feb 7, 2023 |
| Atlantic Equities | Analyst unavailable | $600 | $485.53 | -9.8% | Feb 7, 2023 |
| Oppenheimer | Analyst unavailable | $247 | $483.2 | -62.9% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $268 | $483.2 | -59.7% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $273 | $420.63 | -58.9% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $543 | $435.78 | -18.3% | Nov 15, 2022 |
| Stifel Nicolaus | Analyst unavailable | $500 | $355.62 | -24.8% | Jun 24, 2022 |
| Goldman Sachs | Analyst unavailable | $530 | $357.33 | -20.3% | May 19, 2022 |
| Barclays | Balaji Prasad | $700 | $364.5 | +5.3% | May 6, 2022 |
Track every rating change on IDXX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationIDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services.…
Historical context
All IDXX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -14.0% | Axsome reports Q3 growth led by AUVELITY; pipeline advances |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +9.5% | Tempus pairs Q3 growth with new partnerships and execution risks |
| SNY Sanofi | FY2026 Q3 · Calendar Q4 2026 | +30.8% | +2.8% | Sanofi lifts 2026 outlook as Dupixent and launches drive Q3 growth |
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
Latest beats and misses
Who reports nextBeat on EPS
- SNYFY2026 Q3 · October 30, 2026+30.8% EPS+2.8% move
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the IDXX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-02T16:04:46.057686+00:00
- FN2 earnings calendar · 2026-11-02T01:23:13.261602+00:00
- Polygon adjusted daily market bars · 2026-11-02T17:20:45.534001+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-02T17:20:45.531361+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-02. For educational purposes only; not investment advice.